课件：在高血压伴糖尿病患者中的临床价值.ppt

25. Coca A. et al Clin Ther. 2003;25(11):2849–2864 26. 孙宁玲, 等. 中华心血管病杂志, 2005, 33(7): 618-621. * Effect of Previous Antihypertensive Therapy on the Efficacy of Initial Treatment of Moderate and Severe Hypertension with Irbesartan/HCTZ（COA003） S. Franklin, MD1; J. Neutel, MD2 Presented at the 24th Annual Scientific Meeting of the American Society of Hypertension, May 6-9, 2009, San Francisco, CA. OBJECTIVE The objective of this analysis was to examine the efficacy and safety of irbesartan/HCTZ compared with irbesartan in patients with and without previous antihypertensive therapy. This report is a post hoc analysis of 2 previously published, multicenter, randomized, double-blind, active-controlled, force-titration studies of patients with moderate or severe hypertension.4,5 The moderate hypertension study included adult patients with a sitting systolic blood pressure (SBP) of 160 to 179 mm Hg or a sitting diastolic blood pressure (DBP) of 100 to 109 mm Hg. Patients with SBP ≥180 mm Hg or DBP ≥110 mm Hg were excluded. The severe hypertension study included adult patients with DBP of ≥110 mm Hg in untreated patients and ≥100 mm Hg in those currently receiving antihypertensive monotherapy. Patients were excluded if they had SBP ≥220 mm Hg or DBP ≥130 mm Hg. In both studies, patients received either fixed-dose irbesartan/HCTZ (150 mg/12.5 mg titrated to 300 mg/25 mg) or irbesartan monotherapy (150 mg titrated to 300 mg) for 7 (severe hypertension study) or 12 weeks (moderate hypertension study). This analysis assessed efficacy and safety measurements at baseline and Weeks 1 and 7 in the severe hypertension study or Weeks 2 and 8 in the moderate hypertension study. End points of this analysis were defined as the percentage of patients who attained their BP goal (SBP/DBP 140/90) at Week 7 (severe hypertension study) or Week 8 (moderate hypertension study) and change from baseline BP at Weeks 1 and 7 (severe hypertension study) and Weeks 2 and 8 (moderate hypertens